[The clinical use of Amoxiclav in patients with suppurative meningoencephalitis].
Clinical use of Amoxiclav showed high therapeutic efficacy in patients with purulent meningoencephalitis both alone and in combination with cefalosporinum of the first generation. Against the background of treatment of patients with overt manifestations of meningoencephalitis and neurotoxicosis meningeal and encephalitic manifestations got attenuated during the first week, with liquorodynamics being stabilized, cerebrospinal fluid ameliorating by day 8-10 of the disease course. Bacteriologic assays showed that up to 83.4% of bacterial flora most common in Ukraine are sensitive to Amoxiclav, with such pathogenic organisms as Pneumococcus, Meningococcus, hemophilia bacillus that are actually main pathogens implicated in acute meningoencephalitis in Ukraine being sensitive to the above drug preparation in 100% of cases.
V V
VV
Kononenko
V I
VI
Matiash
L G
LG
Vasilenko
N V
NV
Okruzhnov
Zh P
ZhP
Sidorova
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000008:administration & dosage* / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D008590:Meningoencephalitis / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D008826:Microbial Sensitivity Tests; D012189:Retrospective Studies
D019980:Amoxicillin-Potassium Clavulanate Combination